# An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Study · id `cardio:ct-nct02962648` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02962648](<https://clinicaltrials.gov/study/NCT02962648>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02962648

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02962648. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-09 (actual); primary completion 2018-06-12 (actual). Results posted on 2020-03-10.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Started: 2017-01-09 (actual) (ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Primary completion: 2018-06-12 (actual) (ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Completion: 2018-06-12 (actual) (ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Results first posted: 2020-03-10 (ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02962648, source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02962648-2020-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
- Acronym: FERWON-EXT
- Condition: Iron Deficiency Anemia
- Condition: Iron Deficiency Anaemia
- Intervention (Drug): Iron isomaltoside/ferric derisomaltose
- Lead sponsor: Pharmacosmos A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Pharmacosmos A/S (`cardio:org-pharmacosmos-a-s`)

## Provenance

Content hash: 59a6d0f2640091a29d64d9ccf7e5e9f7d6660f3c216329fb45bd1140112d1891
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
